Bashir, a former general manager of Dubai-based business conglomerate Al Batha group, has more than 14 years of experience in strategic management and operations.
“Adnan’s wealth of experience will add significant value to our Board. We look forward to working with him as we restore FSD,” FSD Pharma co-chairman Anthony Durkacz said in a statement.
READ: FSD Pharma throws resources behind legacy anti-inflammatory drug as potential coronavirus therapy
The company said Bashir was appointed to fill the vacancy on the board following the resignation of Frank Lavelle.
FSD Pharma’s board is now comprised of Anthony Durkacz, Zeeshan Saeed, Nitin Kaushal, Lawrence (Larry) Latowsky, Fernando Cugliari, Donal Carroll and Adnan Bashir.
FSD Pharma is a publicly-traded holding company that owns subsidiary FSD Pharma BioSciences Inc, a specialty biotech pharmaceutical R&D firm focused on developing multiple applications of its lead anti-inflammatory drug FSD-201.
The drug is now one of several therapeutics being advanced that could help reduce severe and deadly lung infection in coronavirus (COVID-19) patients.
Contact Sean at firstname.lastname@example.org